242 Wythe Ave #4, Brooklyn, NY 11249
1-090-1197-9528
office@ourbusiness.com
Khalid-Islam

Khalid Islam

Khalid Islam

 

With over 30 years of experience in Biotech & Pharma and a decade in academia, Khalid Islam has been a transformative force in the industry. His leadership has resulted in companies raising over $1.5 billion globally, engaging in M&A transactions exceeding $22 billion. Notable FDA and EMA-approved products under his leadership include Defitelio, Trodelvy, and Pedmark, with several drugs in clinical development. Currently serving as Chairman of the Board of Nasdaq-listed companies Fennec Pharma Inc. and Gain Therapeutics Inc., as well as private company Minoryx Therapeutics S.L., Khalid Islam has been a significant component of numerous boards, including Immunomedics and Molmed SpA. and Karolinska Development (KDEV; Stockholm, Member of the Investment Committee). As a founder or co-founder, he has played crucial roles in companies such as, Nuprim LLC, and Gain Therapeutics. Khalid Islam’s was CEO of Gentium S.p.A., leading to a $1 billion M&A with Jazz Pharma.